US1888186A - Complex glucosaminic acid salts of the metals of the iron group - Google Patents

Complex glucosaminic acid salts of the metals of the iron group Download PDF

Info

Publication number
US1888186A
US1888186A US573298A US57329831A US1888186A US 1888186 A US1888186 A US 1888186A US 573298 A US573298 A US 573298A US 57329831 A US57329831 A US 57329831A US 1888186 A US1888186 A US 1888186A
Authority
US
United States
Prior art keywords
complex
metals
glucosaminic acid
salts
iron group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US573298A
Inventor
Stoll Arthur
Hofmann Albert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FIRM OF CHEMICAL WORKS FORMERL
FIRM OF CHEMICAL WORKS FORMERLY SANDOZ
Original Assignee
FIRM OF CHEMICAL WORKS FORMERL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FIRM OF CHEMICAL WORKS FORMERL filed Critical FIRM OF CHEMICAL WORKS FORMERL
Application granted granted Critical
Publication of US1888186A publication Critical patent/US1888186A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/02Iron compounds
    • C07F15/025Iron compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/04Nickel compounds
    • C07F15/045Nickel compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/06Cobalt compounds
    • C07F15/065Cobalt compounds without a metal-carbon linkage

Definitions

  • the present invention relates to the prep-' aration of complex glucosaminic acid salts of the metals of the iron group which possess valuable therapeutical properties.
  • the derivatives of metals in order that they can be used in the therapy must possess some special properties, such' as for example a small toxicity, a good toleration on injection and a sufficient solubility.
  • the first two properties depend on the chem ical constitution of the compound, which for this purpose must possess a neutral character and in which the metal must be linked in a complex manner, whereas the solubility in water generally depends on the presence of an acid group which is neutralized with an alkali metal or on the presence of several hydroxylic groups in the molecule.
  • the glucosaminic acid yields such metal salts, that completely fulfil the above cited requirements. They are very stable and contain probably a five ring, as shown by the following fOIIDIl lae, like the heavy metal salts of other amino acids, e. the'copper salt of glycocoll (see P. Pfeifier Organische MolekiilENSen, 1922, page 176)
  • the capacity for the formation of complex compounds is further increased by the presence of the alcoholic hydroxylic groups contained in the molecule of the glucosaminic acid, as it is well known that the polyoxycarboxylic acids such as tartaric acid give complex metal compounds.
  • the metal compounds of the glucosaminic acid containing in their molecule besides one amino group several hydroxylic groups possess a much better stability of the metalcomplex, produce a smaller irritation of the tissues on injection and are much better tolerated, in comparison with metal compounds of the oxyand polyoxy-carboxylic acids that do not contain an amino group.
  • the new compounds pre-' pared according to the present process possess quite a sufiicient solubility for the therapeutical application and may, therefore be successfully used.
  • the new compounds By treating the glucosaminic acid with oxides or hydroxides of the metals the new compounds maybe obtained; The same result is reachedif an equivalent quantity of an organic or an inorganic base is added to a solution containing the glucosaminic acid and the heavy'metalsalt, whereby the metal hydroxide obtained in statu nasc-endi reacts with the glucosami'nic acid.
  • the metal chlorides it is preferable to produce the metal hydroxides by means of an addition of diethylamine or of similar bases, the chlorides of which are soluble in alcohol andmay therefore be easily separated from the metal salts of the glucosaminic acid which are insoluble-therein.
  • the heavy metal salts ofthe glucosaminic acid do not yield with alkali or with other basic compounds a precipitation of the heavy metal hydroxide, but they give the easily soluble double salts of heavy metal and alkali metal or aminosalts of the glucosaminlc acid.
  • Example 1 To a solution of 1 part of glucosaminic acid C. 1 part of nickel carbonate, whereby carbon dioxide escapes and the solution becomes blue. After 10 minutes the solution is separated from the excess of nickel carbonate by filtration and the hot filtrate obtained is diluted with 10 parts of hot alcohol of The crystallization of nickel glucosaminate begins immediately. Pale blue crystals of the. composition (C H O N) Ni.containing 12.96%
  • Example 3 A concentrated aqueous solution containing one molecule of glucosaminic acid and one molecule of ferric chloride is treated with 3 molecules of diethylamine, whereby the solution becomes colored in a deep brown-red shade. By introducing this solution into absolute alcohol the iron glucosaminate is precipitated in form of rusty-brown flocks.
  • the product thus obtained contains generally traces of chlorine; In order to separate them, the salt is again dissolved in a small quantity of water and reprecipitated by introdu-cing the aqueous solution into alcohol containing a small amount of di-ethylamine and eventually a certain quantity of ether.
  • a rusty-brown powder of the composition C H O NFe is obtainedin this manner. It contains 23.1% of Fe (theor. 22.5%).
  • Similar salts may also be prepared from salts of the bivalent and trivalent manganese salts. They are also soluble in water with a brown coloration and yield stable aqueous solutions. 7
  • the complex glucosaminic acid salts of the iron group prepared by interaction of the glucosaminic acid with salts of the metalsof the iron group, which constitute in dry state nonhygroscopic powders, soluble in water, yielding stable solutions and which give with basic compounds easily soluble salts;

Description

Patented-Nov. 15, 1932 UNITED STATES ARTHUR STOLL AND ALBERT HOFMANN, OF BASEL, SWITZERLAND, ASSIGNORS TO FIRM OF GHEMIGAL WORKS FORMERLY SANDOZ, OF BASEL, SWITZERLAND..
PATENT OFFICE COMPLEX eLUcosAmmcAcIn sans or ran META sor THE momv G OUP No Drawing. A pplication filed November 5, 1931, Serial no; 573,298, and in Germany November 10, 1930.
The present invention relates to the prep-' aration of complex glucosaminic acid salts of the metals of the iron group which possess valuable therapeutical properties.
It isknown that the derivatives of metals in order that they can be used in the therapy, must possess some special properties, such' as for example a small toxicity, a good toleration on injection and a sufficient solubility. The first two properties depend on the chem ical constitution of the compound, which for this purpose must possess a neutral character and in which the metal must be linked in a complex manner, whereas the solubility in water generally depends on the presence of an acid group which is neutralized with an alkali metal or on the presence of several hydroxylic groups in the molecule.
It has now been found, that the glucosaminic acid yields such metal salts, that completely fulfil the above cited requirements. They are very stable and contain probably a five ring, as shown by the following fOIIDIl lae, like the heavy metal salts of other amino acids, e. the'copper salt of glycocoll (see P. Pfeifier Organische Molekiilverbindungen, 1922, page 176) The capacity for the formation of complex compounds is further increased by the presence of the alcoholic hydroxylic groups contained in the molecule of the glucosaminic acid, as it is well known that the polyoxycarboxylic acids such as tartaric acid give complex metal compounds. The metal compounds of the glucosaminic acid, containing in their molecule besides one amino group several hydroxylic groups possess a much better stability of the metalcomplex, produce a smaller irritation of the tissues on injection and are much better tolerated, in comparison with metal compounds of the oxyand polyoxy-carboxylic acids that do not contain an amino group. As compared to the complex heavy metal salts of the usual aminoacidsv which contain no oronly "one hydroxylic group andwhic'h owing to their bad solubility present no interest for therapeutical purposes, the new compounds pre-' pared according to the present process possess quite a sufiicient solubility for the therapeutical application and may, therefore be successfully used.
According to the literature, some normal metal salts. of the glucosaminicacid, such as the copper, zinc and silver salts have 2.1-
ready been prepared for the purpose of characterizing this acid (see E. Fischer & F. Thiemann, Ber. 27, page 144, 1894). But from this publication it could not at all be foreseen, that the glucosaminic acid would yield with other metals therapeutically valuable and complex compounds, for the reason, that the described copper salt is insoluble-in. water and the silver salt is unstable and is decomposed under reduction to the metal. 'wm a .For the preparation of the new compounds several methodsmay be used.
By treating the glucosaminic acid with oxides or hydroxides of the metals the new compounds maybe obtained; The same result is reachedif an equivalent quantity of an organic or an inorganic base is added to a solution containing the glucosaminic acid and the heavy'metalsalt, whereby the metal hydroxide obtained in statu nasc-endi reacts with the glucosami'nic acid. In the case where the sulphates of the heavy metals are used it islindicated to employ barium hydrox ide, because the precipitated barium sulphate can easily be separated from the solution; By using the metal chlorides, it is preferable to produce the metal hydroxides by means of an addition of diethylamine or of similar bases, the chlorides of which are soluble in alcohol andmay therefore be easily separated from the metal salts of the glucosaminic acid which are insoluble-therein. 1
i It is further also possible to treat an aqueone solution oftheglucosaminic acid with a carbonate of a heavy metal, whereby the carbonate is'dis solvedunder production of 7 carbon dioxide, although the glucosaminic in 20 parts of water is added at 95 salts which correspond to the valency of the metals and which are generally well crystal lized, also such compounds of the glucosaminic acid that contain two, three or several times more of a metal than corresponds to the normal stochiometric proportion. Such salts are distinguished by a good solubility.
The heavy metal salts ofthe glucosaminic acid do not yield with alkali or with other basic compounds a precipitation of the heavy metal hydroxide, but they give the easily soluble double salts of heavy metal and alkali metal or aminosalts of the glucosaminlc acid.
- The new process is illustrated by the following examples, which are not limitative,
the parts being by weight. Example 1 To a solution of 1 part of glucosaminic acid C. 1 part of nickel carbonate, whereby carbon dioxide escapes and the solution becomes blue. After 10 minutes the solution is separated from the excess of nickel carbonate by filtration and the hot filtrate obtained is diluted with 10 parts of hot alcohol of The crystallization of nickel glucosaminate begins immediately. Pale blue crystals of the. composition (C H O N) Ni.containing 12.96%
* of Ni (theor. 13.1%) areobtained. By dissolving one molecule of nickel glucosaminate in one molecule of a 2-n-sodium hydroxide solution a dark blue solution is obtained from which the nickel-sodiumgluoosaminate of the composition (C H O N) Ni] Na is precipitated by means of absolute alcohol.
By dissolving one molecule of, nickelglucosaminate in 2 molecules of sodium hydroxide an intensively green colored nickel glucosaminate is obtained. 2 1
Ewample 2 To a solution of 1 part of glucosaminic acid in 20 parts of water is added at 95 C. one part of cobalt carbonate, whereby carbon dioxide escapes and the solution becomes the solution is filtered and the filtrate introduced into parts ofabsolute alcohol. The very easily soluble cobalt glucosaminate is obtained in form of a wine-red powder of the composition (C H O N) Co. 65
By working as described in Examplel the respective cobalt-alkalimetalglucosaminates may be prepared.
Example 3 A concentrated aqueous solution containing one molecule of glucosaminic acid and one molecule of ferric chloride is treated with 3 molecules of diethylamine, whereby the solution becomes colored in a deep brown-red shade. By introducing this solution into absolute alcohol the iron glucosaminate is precipitated in form of rusty-brown flocks. The product thus obtained contains generally traces of chlorine; In order to separate them, the salt is again dissolved in a small quantity of water and reprecipitated by introdu-cing the aqueous solution into alcohol containing a small amount of di-ethylamine and eventually a certain quantity of ether. A rusty-brown powder of the composition C H O NFe is obtainedin this manner. It contains 23.1% of Fe (theor. 22.5%).
By replacing the ferric chloride by a salt of the bivalent iron, a similar complex salt is obtained. Its aqueous solutions are dark green, but change the color on oxidation by air.
Similar salts may also be prepared from salts of the bivalent and trivalent manganese salts. They are also soluble in water with a brown coloration and yield stable aqueous solutions. 7
What we claim is:
The complex glucosaminic acid salts of the iron group, prepared by interaction of the glucosaminic acid with salts of the metalsof the iron group, which constitute in dry state nonhygroscopic powders, soluble in water, yielding stable solutions and which give with basic compounds easily soluble salts;
In witness whereof we have hereunto signed our names this 27th day of October,
ARTHUR STOLL. ALBERT HOFMANN.
. colored to deep wine-red. After 30 minutes
US573298A 1930-11-11 1931-11-05 Complex glucosaminic acid salts of the metals of the iron group Expired - Lifetime US1888186A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE564437T 1930-11-11

Publications (1)

Publication Number Publication Date
US1888186A true US1888186A (en) 1932-11-15

Family

ID=34559089

Family Applications (1)

Application Number Title Priority Date Filing Date
US573298A Expired - Lifetime US1888186A (en) 1930-11-11 1931-11-05 Complex glucosaminic acid salts of the metals of the iron group

Country Status (2)

Country Link
US (1) US1888186A (en)
DE (1) DE564437C (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2474989A (en) * 1944-07-07 1949-07-05 Hoffmann La Roche Injectable iron preparation and process for the manufacture of same
US3077488A (en) * 1959-03-12 1963-02-12 Robert M Mercier Method of oxidizing ferrous salts into ferric salts in the presence of a gas containing free oxygen
US3102844A (en) * 1960-02-02 1963-09-03 American Cyanamid Co Oral iron-glucosamine hematinic composition and therapy

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2474989A (en) * 1944-07-07 1949-07-05 Hoffmann La Roche Injectable iron preparation and process for the manufacture of same
US3077488A (en) * 1959-03-12 1963-02-12 Robert M Mercier Method of oxidizing ferrous salts into ferric salts in the presence of a gas containing free oxygen
US3102844A (en) * 1960-02-02 1963-09-03 American Cyanamid Co Oral iron-glucosamine hematinic composition and therapy

Also Published As

Publication number Publication date
DE564437C (en) 1932-11-18

Similar Documents

Publication Publication Date Title
DE2332878C2 (en) Salts of cephalosporins with arginine and lysine, their manufacture and injectable pharmaceutical preparations
DE2309582C3 (en) Process for obtaining pure 7-dimethylamino-6-desmethyl-6-deoxytetracycline hydrochloride from its crude aqueous solutions and the complex compound with calcium chloride formed in the process
US1888186A (en) Complex glucosaminic acid salts of the metals of the iron group
DE1906527B2 (en) Thionine derivatives, processes for their production and pharmaceutical preparations containing them
US2135111A (en) Vanadyl lactate and process of making it
DE1493403A1 (en) Process for the resolution of racemates into their optical isomers
DE1081880B (en) Process for the production of titanium (III) acetylacetonate
DE609928C (en) Process for the preparation of 2-amino-1-oxynaphthalene-8-sulfonic acid
AT135347B (en) Process for the preparation of complex, therapeutically valuable, organic heavy metal compounds.
US1101734A (en) Iron salts of high molecular fatty acids containing arsenic and a halogen.
US1983414A (en) Bile acid amides and their preparation
US2127374A (en) Process of making an iron compound of nitroso-beta-naphthol
US1101733A (en) Salts of high molecular fatty acids containing arsenic and a halogen.
AT205659B (en) Process for the production of new amino acid = iron salt complexes
DE3309762C1 (en) Process for the production of D, L-homocystine (II)
DE733312C (en) Manufacture of manganese pigments
DE699555C (en) Process for the preparation of pyridinecarboxylic acids
US2801246A (en) Metal complexes of hydrazide-hydrazones and process for producing the same
DE254187C (en)
US888321A (en) Arsenoarylglycin.
DE914250C (en) Process for the production of new, stable, heavy metal-containing poly-iminoisoindolenines
US252202A (en) Otto fischee
DE2136622A1 (en)
DE605191C (en) Process for the preparation of 1-amino-2íñ3-dimethylanthraquinone
US2089197A (en) Zinc hydroxylates of esters of parahydroxybenzoic acid and process for producing the same